1. Home
  2. KRP vs VIR Comparison

KRP vs VIR Comparison

Compare KRP & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimbell Royalty Partners

KRP

Kimbell Royalty Partners

HOLD

Current Price

$15.18

Market Cap

1.4B

Sector

Energy

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.10

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRP
VIR
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
KRP
VIR
Price
$15.18
$9.10
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$17.33
$19.43
AVG Volume (30 Days)
949.4K
1.4M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
10.25%
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
$333,830,000.00
$68,556,000.00
Revenue This Year
$6.88
$270.22
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.93
N/A
52 Week Low
$11.31
$4.16
52 Week High
$15.65
$11.66

Technical Indicators

Market Signals
Indicator
KRP
VIR
Relative Strength Index (RSI) 54.60 45.13
Support Level $14.10 $8.47
Resistance Level $15.65 $10.29
Average True Range (ATR) 0.32 0.41
MACD -0.01 -0.08
Stochastic Oscillator 71.84 30.57

Price Performance

Historical Comparison
KRP
VIR

About KRP Kimbell Royalty Partners

Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: